Moxazocine

This classification denotes an analgesic agent with the molecular formula C18H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BNB57S7DWT, chemically known as 2,6-methano-3-benzazocin-8-ol, 3-(cyclopropyl-methyl)-1,2,3,4,5,6-hexahydro-11-methoxy-6-methyl-,(2r-(2 alpha, 6 alpha, 11r*))-; but generally known as moxazocine, which bears US NIH Compound Identifier 3047776. European Medicines Agency schedules Moxazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09083MIG. The term MOXAZOCINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). MOXAZOCINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moxazocine under HS 29333999 and SITC 51574. As of Q4 2014, MOXAZOCINE remains the US FDA Preferred Term for this commodity. Moxazocine bears US NLM identifiers UMLS ID C2983815 and NCI Concept Code C90644. SMILES: O(C1C2(CCN(C1CC1C2CC(O)CC1)CC1CC1)C)C.